Revolution Medicines GAAP EPS of -$1.14 misses by $0.28, revenue of $0.7M misses by $0.5M

• Revolution Medicines press release (NASDAQ:RVMD): Q4 GAAP EPS of -$1.14 misses by $0.28.
• Revenue of $0.7M (-95.4% Y/Y) misses by $0.5M.

More on Revolution Medicines

• Revolution Medicines Is Hard To Understand
• Corvex Management buys Illumina, exits Apple, TKO
• Seeking Alpha’s Quant Rating on Revolution Medicines
• Historical earnings data for Revolution Medicines
• Financial information for Revolution Medicines